Burton, Anya
Balachandrakumar, Vinay K. http://orcid.org/0000-0002-8906-2747
Driver, Robert J. http://orcid.org/0000-0001-8130-6164
Tataru, Daniela
Paley, Lizz
Marshall, Aileen
Alexander, Graeme
Rowe, Ian A.
Palmer, Daniel H.
Cross, Tim J. S. http://orcid.org/0000-0003-0625-8726
,
Article History
Received: 22 December 2020
Revised: 14 June 2021
Accepted: 21 July 2021
First Online: 26 November 2021
Competing interests
: All of the authors completed the ICMJE uniform disclosure form; Professor Alexander, Dr. Tataru, Ms. Paley, Dr. Marshall and Dr. Driver have nothing to disclose. During the conduct of the study, Dr. Burton reports grants from BTG International Ltd and Dr. Balachandrakumar, Dr. Cross and Professor Palmer report grants from Sirtex, Bristol-Myers-Squibb and Bayer. Dr Cross reports personal fees from Bayer. Outside the submitted work, Dr. Cross reports personal fees from Eisai pharmaceuticals, Bayer, AstraZeneca and Roche and Professor Palmer reports grants and personal fees from Bristol-Myers-Squibb, AstraZeneca, MSD and Nucana Inc, and personal fees from Eisai, Bayer, and Roche. Dr. Rowe reports personal fees from Roche, non-financial support from Abbvie, outside the submitted work.
: PHE has been granted specific legal permission to collect information about patients with cancer for specific purposes, without the need to seek consent. These purposes include health improvement and service provision. This permission was granted to PHE through Section 251 of the NHS Act 2006. This support is reviewed annually by the Confidentiality Advisory Group of the Health Research Authority.
: Not applicable.